<?xml version="1.0" encoding="UTF-8"?>
<p>The glucocerebrosidase gene (
 <italic>GBA</italic>) encodes the lysosomal enzyme β-glucocerebrosidase. Mutations and polymorphisms in 
 <italic>GBA</italic> are estimated to be found in up to 12% of patients with PD of European descent, and mutations in 15%–20% of Ashkenazi Jewish cases, making 
 <italic>GBA</italic> the most significant genetic risk factor for PD.
 <sup>
  <xref rid="R1" ref-type="bibr">1</xref>
  <xref ref-type="bibr" rid="R2">–</xref>
  <xref rid="R5" ref-type="bibr">5</xref>
 </sup>
 <italic>GBA</italic>-associated PD has been shown to manifest at a younger age and with a lower median survival time from diagnosis compared to idiopathic PD.
 <sup>
  <xref rid="R6" ref-type="bibr">6</xref>
  <xref ref-type="bibr" rid="R7">–</xref>
  <xref rid="R8" ref-type="bibr">8</xref>
 </sup> Further, 
 <italic>GBA</italic> mutation status is an independent risk factor for cognitive impairment.
 <sup>
  <xref rid="R3" ref-type="bibr">3</xref>,
  <xref rid="R5" ref-type="bibr">5</xref>,
  <xref rid="R9" ref-type="bibr">9</xref>
  <xref ref-type="bibr" rid="R10">–</xref>
  <xref rid="R11" ref-type="bibr">11</xref>
 </sup>
</p>
